CARLSBAD, Calif., May 30, 2012 /PRNewswire/ -- The formation of a new Contract Research Organization (CRO), Agility Clinical, Inc., was announced today. Agility will focus on providing customized clinical research and consulting services to small and virtual biotechnology, specialty pharma, medical device and diagnostic companies. The Company was formed by David F. Hale, Chairman and CEO of Hale BioPharma Ventures, LLC.
According to Hale, "Agility's mission is to provide services to small and virtual biopharma companies, with a focus on treatments or diagnoses for children and orphan diseases. While Agility will provide traditional CRO services, companies may also choose from a menu of services that addresses their specific needs. The executive management team is comprised of individuals with strong experience in all phases and functional areas of clinical trials."
Hale, who has been a key figure in the Southern California life sciences industry for over 25 years, has been involved as founder, CEO or chairman of several companies, including Hybritech, Inc., Gensia, Inc., Viagene, Inc., Santarus, Inc., Somaxon Pharmaceuticals, SkinMedica, Inc., Neurelis, Inc., and a number of others. Hale will serve as Chairman of the Board and has recruited an executive management team of industry veterans who have significant experience in the design, execution, and completion of clinical trials, including Ellen Morgan, Marilyn Carlson, DMD, MD, Elizabeth Ludington, PhD, Kristi Clark, MBA, and Ali Sadighian.
Morgan, who will serve as CEO, brings 30 years of industry experience to Agility. She co-founded and was CEO and chairman of Synteract, Inc., a California-based CRO which grew to over 300 employees, and provided clinical services to hundreds of companies. She is also founder and CEO of the first non-profit CRO, Public Health Alliance for Clinical Trials (PHACT), whose mission is to conduct clinical trials fo
|SOURCE Agility Clinical, Inc.|
Copyright©2010 PR Newswire.
All rights reserved